Appili Therapeutics Inc.
APLIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | 0.00 | -0.03 | 0.08 |
| FCF Yield | -32.13% | -0.28% | 24.00% | -9.07% |
| EV / EBITDA | -13.28 | -18.52 | 16.56 | -1,947.75 |
| Quality | ||||
| ROIC | 32.95% | 47.39% | 5.00% | -20.82% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.77 | 0.01 | 4.54 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -33.25% | -33.01% | -33.01% | 499,561.10% |
| Free Cash Flow Growth | -11,847.39% | -100.61% | 333.42% | -208.76% |
| Safety | ||||
| Net Debt / EBITDA | -11.07 | -15.40 | 11.92 | -1,352.60 |
| Interest Coverage | 0.00 | -2.17 | -0.09 | 0.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 174.56 | 0.00 | -11,929.13 | 1,461.37 |